The vaccines are also easier to make and multivalent shots can be formulated in prefilled syringes, said Vicebio chief executive Emmanuel Hanon, who was formerly GSK's vaccine chief. New Cambridge ...

CDC's RSV vaccine recommendations from Pfizer and GSK face review by HHS advisor William "Reyn" Archer III. Read more here.

GSK on Wednesday said it was "well positioned" to absorb potential U.S. pharmaceutical tariffs, citing AI-driven cost cuts ...

GSK plc's stock price has significantly outperformed the healthcare sector this year, supported by its healthy Q1 2025 ...

BNP Paribas Exane analyst Peter Verdult initiated coverage of GSK (GSK) with a Neutral rating and $35.25 price target Discover outperforming stocks and invest smarter with Top Smart Score Stocks.

In a report released today, Jo Walton from UBS maintained a Hold rating on GlaxoSmithKline (GSK – Research Report), with a price target of p1,600.00. The company’s shares opened today at p1 ...

Uncertainty continues to hang over the latest round of financial results and forecasts for companies both big and small as ...

GSK Plc reported better-than-expected profit in the first quarter as sales from its asthma and HIV drugs offset a lackluster vaccine performance. The UK drugmaker’s shares surged after it ...

GSK has been found guilty of bringing discredit on the pharma industry after a complainant flagged “a shocking error” in the prescribing information for the JAK inhibitor Omjjara. A person who ...

As GSK weathers the storm of sinking vaccine sales and gears up for key launches in its specialty medicines sector, the British drug giant feels prepared for any challenges that U.S. drug import ...